Jeremy Springhorn
Chief Executive Officer at Nido Biosciences
Boston, Massachusetts
Overview
Work Experience
Chief Executive Officer
2021 - Current
Nido Biosciences is a clinical-stage company that develops precision medicines for severe neurological diseases.
Raised $109,000,000.00 from Bioluminescence Ventures.
Independent Director
2019
Board Member
2017
Member Of The Board Of Advisors
2017 - 2024
Mythic Therapeutics is a biotechnology company focused on a new generation of groundbreaking cancer therapeutics.
Raised $126,599,251.00 from Venrock Healthcare Capital Partners, Venrock, First Round Capital, Foresite Capital, OMX Ventures, Refactor, Perceptive Advisors, Highside Capital Management, Viking Global Investors and Lifeforce Capital.
Chief Business Officer
2017 - 2021
Syros Pharmaceuticals is a life sciences company that focuses on treating diseases by mapping gene regulatory circuits.
Raised $620,470,018.00 from Deep Track Capital, Flagship Pioneering, Adage Capital Management, Samsara BioCapital, Blue Owl, Invus, Bain Capital Life Sciences, Dafna Capital Management, Ally Bridge Group and Bain Capital Life Sciences.
Partner, Corporate Development
2015 - 2017
Flagship Pioneering is a venture capital firm that invests in life sciences and healthcare companies.
VP, Corporate Strategy and Business Development
2009 - 2015
Alexion Pharmaceuticals is a biopharmaceutical company that engages in the development and commercialization of mid-to-late-stage therapies.
Raised $5,800,000.00.
Head of Global Business Development and Corporate Strategy
2006 - 2008
Alexion Pharmaceuticals is a biopharmaceutical company that engages in the development and commercialization of mid-to-late-stage therapies.
Raised $5,800,000.00.
R&D Management
1992 - 2006
Alexion Pharmaceuticals is a biopharmaceutical company that engages in the development and commercialization of mid-to-late-stage therapies.
Raised $5,800,000.00.